We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
Read MoreHide Full Article
Key Takeaways
Amvuttra drove $801.9 million in H1 2025 sales, up 89% year over year.
U.S. and EU nods expanded Amvuttra's use to ATTR-CM, boosting uptake.
Competition from Pfizer's Vyndaqel and BridgeBio's Attruby poses challenges.
Alnylam Pharmaceuticals (ALNY - Free Report) is a commercial-stage company that currently markets four drugs. The company first received regulatory approval in 2018 for Onpattro to treat adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Subsequently, ALNY received approval for Givlaari (acute hepatic porphyria), Oxlumo (primary hyperoxaluria type 1) and Amvuttra (polyneuropathy of hATTR amyloidosis).
Currently, Amvuttra (vutrisiran), its newest drug, is Alnylam’s primary top-line driver. The drug generated $801.9 million in global sales in the first half of 2025, representing a staggering 89% year-over-year growth. The drug’s solid uptake has been driven by new patients starting treatment as well as several patients switching from Onpattro.
In the first half of 2025, Alnylam received approval in the United States and the EU for the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. The latest nods make Amvuttra the first and only RNAi therapeutic approved in the United States and the EU for both ATTR-CM and hATTR-PN in adults, marking a significant milestone achievement.
This label expansion likely aided sales of the drug in the first half of 2025 and is expected to continue boosting uptake in the second half. Alnylam also expects approvals for Amvuttra for the ATTR-CM indication in several other geographies this year. This will expand the eligible patient population for the drug, driving substantial growth for the company in the future.
ALNY’s Competition in the Market for ATTR Treatments
Alnylam’s Amvuttra faces notable competition in the ATTR-CM market from Pfizer’s (PFE - Free Report) Vyndaqel/Vyndamax (tafamidis) and BridgeBio’s (BBIO - Free Report) Attruby (acoramidis), both of which are already approved for this indication. While Amvuttra is positioned with a differentiated clinical profile, Pfizer’s and BridgeBio’s therapies carry the advantage of oral administration and comparatively lower list prices in the United States. These factors could influence prescribing decisions and pose challenges to Alnylam’s competitive positioning in this space.
Vyndaqel is one of the key in-line products that has driven improvement in Pfizer’s revenues in the first half of 2025. Global Vyndaqel family revenues of $3.1 billion rose 27% year over year in the first half of 2025, driven by continued demand growth due to increases in diagnosis and treatment rates, primarily in the United States and developed Europe. Pfizer’s Vyndaqel family includes global revenues from Vyndaqel as well as revenues for Vyndamax in the United States and Vynmac in Japan.
Approved in late 2024, Attruby is BridgeBio’s only marketed product. The drug generated sales worth $108.2 million in the first half of 2025, driven by solid uptake. BBIO reported that as of Aug. 1, 2025, 3,751 unique patient prescriptions for Attruby have been written by 1,074 unique healthcare providers since approval. BridgeBio is also currently evaluating acoramidis for the prevention of early-stage variant transthyretin amyloidosis in a late-stage study.
ALNY’s Stock Price, Valuation and Estimates
Shares of Alnylam have surged 93% so far this year compared with the industry’s 3.2% growth. The stock has also outperformed the sector and the S&P 500 index during the same time frame, as seen in the chart below.
ALNY Stock Price Movement
Image Source: Zacks Investment Research
From a valuation standpoint, Alnylam stock is expensive. Going by the price/sales ratio, the company’s shares currently trade at 24.10 trailing 12-month sales per share, much higher than 2.12 for the industry. The stock is also trading above its five-year mean of 20.96.
ALNY Stock Valuation
Image Source: Zacks Investment Research
Estimates for Alnylam’s 2025 earnings have improved from 93 cents to $3.39 per share in the past 60 days, and estimates for 2026 earnings have improved from $3.58 to $8.75 over the same timeframe.
Image: Bigstock
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
Key Takeaways
Alnylam Pharmaceuticals (ALNY - Free Report) is a commercial-stage company that currently markets four drugs. The company first received regulatory approval in 2018 for Onpattro to treat adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Subsequently, ALNY received approval for Givlaari (acute hepatic porphyria), Oxlumo (primary hyperoxaluria type 1) and Amvuttra (polyneuropathy of hATTR amyloidosis).
Currently, Amvuttra (vutrisiran), its newest drug, is Alnylam’s primary top-line driver. The drug generated $801.9 million in global sales in the first half of 2025, representing a staggering 89% year-over-year growth. The drug’s solid uptake has been driven by new patients starting treatment as well as several patients switching from Onpattro.
In the first half of 2025, Alnylam received approval in the United States and the EU for the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. The latest nods make Amvuttra the first and only RNAi therapeutic approved in the United States and the EU for both ATTR-CM and hATTR-PN in adults, marking a significant milestone achievement.
This label expansion likely aided sales of the drug in the first half of 2025 and is expected to continue boosting uptake in the second half. Alnylam also expects approvals for Amvuttra for the ATTR-CM indication in several other geographies this year. This will expand the eligible patient population for the drug, driving substantial growth for the company in the future.
ALNY’s Competition in the Market for ATTR Treatments
Alnylam’s Amvuttra faces notable competition in the ATTR-CM market from Pfizer’s (PFE - Free Report) Vyndaqel/Vyndamax (tafamidis) and BridgeBio’s (BBIO - Free Report) Attruby (acoramidis), both of which are already approved for this indication. While Amvuttra is positioned with a differentiated clinical profile, Pfizer’s and BridgeBio’s therapies carry the advantage of oral administration and comparatively lower list prices in the United States. These factors could influence prescribing decisions and pose challenges to Alnylam’s competitive positioning in this space.
Vyndaqel is one of the key in-line products that has driven improvement in Pfizer’s revenues in the first half of 2025. Global Vyndaqel family revenues of $3.1 billion rose 27% year over year in the first half of 2025, driven by continued demand growth due to increases in diagnosis and treatment rates, primarily in the United States and developed Europe. Pfizer’s Vyndaqel family includes global revenues from Vyndaqel as well as revenues for Vyndamax in the United States and Vynmac in Japan.
Approved in late 2024, Attruby is BridgeBio’s only marketed product. The drug generated sales worth $108.2 million in the first half of 2025, driven by solid uptake. BBIO reported that as of Aug. 1, 2025, 3,751 unique patient prescriptions for Attruby have been written by 1,074 unique healthcare providers since approval. BridgeBio is also currently evaluating acoramidis for the prevention of early-stage variant transthyretin amyloidosis in a late-stage study.
ALNY’s Stock Price, Valuation and Estimates
Shares of Alnylam have surged 93% so far this year compared with the industry’s 3.2% growth. The stock has also outperformed the sector and the S&P 500 index during the same time frame, as seen in the chart below.
ALNY Stock Price Movement
From a valuation standpoint, Alnylam stock is expensive. Going by the price/sales ratio, the company’s shares currently trade at 24.10 trailing 12-month sales per share, much higher than 2.12 for the industry. The stock is also trading above its five-year mean of 20.96.
ALNY Stock Valuation
Estimates for Alnylam’s 2025 earnings have improved from 93 cents to $3.39 per share in the past 60 days, and estimates for 2026 earnings have improved from $3.58 to $8.75 over the same timeframe.
ALNY Estimate Movement
Alnylam currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.